Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Single Nucleotide Polymorphisms-SNPs01:05

Single Nucleotide Polymorphisms-SNPs

A single nucleotide polymorphism or SNP is a single nucleotide variation at a specific genomic position in a large population. It is the most prevalent type of sequence variation found in the human genome. Point mutations that occur in more than 1% of the population qualify as SNPs. These are present once every 1000 nucleotides on an average in the human genome. Replacement of a purine with another purine (A/G) or a pyrimidine with another pyrimidine (C/T) is known as a transition. In contrast,...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Targeting Neuroinflammation in the Piriform Cortex-Amygdala: Enhanced Efficacy of Niosome-Based Sodium Butyrate in Ischemic Stroke.

Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology·2026
Same author

Exploration of Novel Antimicrobial Peptides from Gut Probiotics Enterococcus spp. Against Extensively drug-resistant Pathogens Through cutting-edge Computational Discovery.

Probiotics and antimicrobial proteins·2026
Same author

Niosome-encapsulated sodium butyrate enhances blood-brain barrier integrity and reduces neuroinflammation in a rat model of ischemic stroke.

Brain research bulletin·2026
Same author

Design, Expression, and Binding Interactions Study of the Recombinant Engineered IL-6R.

Iranian journal of pharmaceutical research : IJPR·2025
Same author

Enhanced immunogenicity in mouse by recombinant BCG prime and protein boost based on latency antigen Rv1733c and/or reactivation antigen RpfE.

BMC infectious diseases·2025
Same author

Computational drug discovery of potential 5α-reductase phytochemical inhibitors and hair growth promotion using <i>in silico</i> techniques.

Frontiers in bioinformatics·2025

Related Experiment Video

Updated: Jun 12, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

Novel VKORC1 mutations associated with warfarin sensitivity.

Shadi Baniasadi1, Samira Beizaee, Bahram Kazemi

  • 1Pharmaceutical Care Department, TB and Lung Disease Research Center, Shahid Beheshti University, M.C., Tehran, Iran.

Cardiovascular Therapeutics
|June 29, 2010
PubMed
Summary

Genetic variants in the vitamin K epoxide reductase complex subunit 1 (VKORC1) gene are linked to warfarin sensitivity. Three patients with VKORC1 mutations experienced bleeding, indicating a need for genetic screening to guide warfarin dosing and reduce risks.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Related Experiment Videos

Last Updated: Jun 12, 2026

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes
11:33

Isolation and Kv Channel Recordings in Murine Atrial and Ventricular Cardiomyocytes

Published on: March 12, 2013

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

Area of Science:

  • Pharmacogenomics
  • Cardiovascular Medicine
  • Clinical Genetics

Background:

  • Warfarin is a critical anticoagulant for preventing thromboembolic events.
  • Its efficacy is influenced by genetic factors, particularly the VKORC1 gene.
  • Understanding VKORC1 variants is key to personalized warfarin therapy.

Purpose of the Study:

  • To investigate the impact of VKORC1 genetic variants on warfarin response.
  • To assess polymorphisms in VKORC1 exon 1, exon 3, and the 3'-untranslated region.
  • To correlate VKORC1 mutations with clinical outcomes like bleeding and warfarin dosage.

Main Methods:

  • Genotyping of VKORC1 polymorphisms in 60 patients with stable INR.
  • Analysis of frameshift mutations (91delCC, 51addCT) in VKORC1 exon 3.
  • Comparison of warfarin maintenance doses and bleeding events between patients with and without mutations.

Main Results:

  • Three patients with VKORC1 frameshift mutations (1 with 91delCC, 2 with 51addCT) were identified.
  • All 3 patients with mutations reported bleeding during warfarin use.
  • Warfarin maintenance doses significantly differed between patients with and without VKORC1 mutations.

Conclusions:

  • VKORC1 genetic variants significantly influence warfarin response and bleeding risk.
  • Standard warfarin monitoring may be insufficient for patients with specific VKORC1 mutations.
  • Genetic screening of VKORC1 may be beneficial for guiding warfarin dosing and minimizing bleeding complications.